BOSTON, March 1, 2016 /PRNewswire/ -- Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer of Stealth, will present at the Cowen & Co. 36th Annual Health Care Conference at 12:00 p.m. ET on Tuesday, March 8, 2016 in Boston.
Stealth BioTherapeutics: Leading Mitochondrial Medicine
Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. Stealth's clinical development program is focused along several core therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. More information regarding Stealth and its pipeline is available at StealthBT.com.
SOURCE Stealth BioTherapeutics